Lymphoproliferative syndrome

Summary

Lymphoproliferative syndrome (MONDO:0016537) is a disease (an umbrella term covering 8 Mondo subtypes) caused by ITK (GenCC Definitive), with 3 cohort genes and 105 clinical trials. Top therapeutic interventions include epoetin alfa, amitriptyline, and tabelecleucel.

At a glance

• Causal gene: ITK (GenCC Definitive)
• Umbrella term: 8 Mondo subtypes
• Cohort genes: 3
• ClinVar variants: 1
• Clinical trials: 105

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lymphoproliferative syndrome
Mondo ID	MONDO:0016537
MeSH	D008232
OMIM	308240
Orphanet	238510
DOID	DOID:0060704
NCIT	C9308
SNOMED CT	277466009
UMLS	C0024314
MedGen	6162
GARD	0020633
Is cancer (heuristic)	no

Also known as: lymphoproliferative disorder · lymphoproliferative syndrome

Data availability: 1 ClinVar variant · 2 GenCC gene-disease records.

Disease family

An umbrella term covering 8 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › immune system disorder › inborn error of immunity › lymphoproliferative syndrome

Related subtypes (40): B cell deficiency, complement deficiency, phagocyte bactericidal dysfunction, trichohepatoenteric syndrome, hepatic veno-occlusive disease-immunodeficiency syndrome, immunodeficiency with defective T-cell response to interleukin 1, Say-Barber-Miller syndrome, familial isolated congenital asplenia, X-linked immunoneurologic disorder, ectodermal dysplasia and immune deficiency, immunodeficiency 33, immunodeficiency 47, combined immunodeficiency due to moesin deficiency, immunodeficiency, X-linked, with deficiency of 115,000 Dalton surface glycoprotein, properdin deficiency, X-linked, combined immunodeficiency with faciooculoskeletal anomalies, recurrent infections associated with rare immunoglobulin isotypes deficiency, immunodeficiency 28, autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity, immunodeficiency 37, immunodeficiency 39, BENTA disease, primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection, immunodeficiency 49, chronic mucocutaneous candidiasis, hereditary hemophagocytic lymphohistiocytosis, immunoglobulin heavy chain deficiency, immuno-osseous dysplasia, IL10-related early-onset inflammatory bowel disease, T-cell immunodeficiency with epidermodysplasia verruciformis, Aicardi-Goutieres syndrome, immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome, inflammatory bowel disease-recurrent sinopulmonary infections syndrome, A20 haploinsufficiency, NK cell deficiency, T cell and NK cell immunodeficiency, dendritic cell deficiency, immunodysregulation with variable immunodeficiency and autoimmunity, immune dysregulation with immunodeficiency due to AIOLOS haploinsufficiency, STAT5 haploinsufficiency

Subtypes (8): X-linked lymphoproliferative syndrome, Dianzani autoimmune lymphoproliferative disease, lymphoproliferative syndrome 1, lymphoproliferative syndrome 2, Castleman disease, autoimmune lymphoproliferative syndrome, severe combined immunodeficiency due to CD70 deficiency, atypical lymphoproliferative disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
871639	NM_002351.5(SH2D1A):c.164G>A (p.Arg55Gln)	SH2D1A	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 8 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
ITK	Definitive	Autosomal recessive	lymphoproliferative syndrome 1	5
NFATC2	Moderate	Autosomal recessive	lymphoproliferative syndrome	3

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ITK	Orphanet:538963	Combined immunodeficiency due to ITK deficiency
SH2D1A	Orphanet:538931	X-linked lymphoproliferative disease due to SAP deficiency

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ITK	HGNC:6171	ENSG00000113263	Q08881	Tyrosine-protein kinase ITK/TSK	gencc
NFATC2	HGNC:7776	ENSG00000101096	Q13469	Nuclear factor of activated T-cells, cytoplasmic 2	gencc
SH2D1A	HGNC:10820	ENSG00000183918	O60880	SH2 domain-containing protein 1A	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ITK	Tyrosine-protein kinase ITK/TSK	Tyrosine kinase that plays an essential role in regulation of the adaptive immune response.
NFATC2	Nuclear factor of activated T-cells, cytoplasmic 2	Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF or GM-CSF.
SH2D1A	SH2 domain-containing protein 1A	Cytoplasmic adapter regulating receptors of the signaling lymphocytic activation molecule (SLAM) family such as SLAMF1, CD244, LY9, CD84, SLAMF6 and SLAMF7.

Protein-family classification

Druggable: 1 · Difficult: 2 · Unknown: 0 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	9.2×	0.246
Scaffold/PPI	1	5.8×	0.246
Transcription factor	1	2.8×	0.321

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ITK	Kinase	yes	2.7.10.2	Prot_kinase_dom, SH2, Ser-Thr/Tyr_kinase_cat_dom
NFATC2	Transcription factor	no		IPT_dom, NFAT, p53-like_TF_DNA-bd_sf
SH2D1A	Scaffold/PPI	no		SH2, SH2_prot_1A, SH2D1A_SH2

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
granulocyte	2
thymus	2
blood	1
layer of synovial tissue	1
synovial joint	1
vena cava	1
lymph node	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ITK	198	broad	marker	granulocyte, thymus, blood
NFATC2	230	ubiquitous	marker	vena cava, synovial joint, layer of synovial tissue
SH2D1A	170	broad	marker	thymus, lymph node, granulocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ITK	2,670
NFATC2	2,524
SH2D1A	1,548

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ITK	Q08881	37
NFATC2	Q13469	12
SH2D1A	O60880	6

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 12. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
FCERI mediated Ca+2 mobilization	2	237.9×	3e-04	ITK, NFATC2
Calcineurin activates NFAT	1	423.0×	0.008	NFATC2
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	1	380.7×	0.008	NFATC2
CLEC7A (Dectin-1) induces NFAT activation	1	346.1×	0.008	NFATC2
Adaptive Immune System	2	19.9×	0.008	SH2D1A, ITK
TCR signaling	1	165.5×	0.012	ITK
Generation of second messenger molecules	1	115.3×	0.015	ITK
Fc epsilon receptor (FCERI) signaling	1	90.6×	0.016	ITK
Immune System	2	8.6×	0.023	SH2D1A, ITK
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	1	48.8×	0.024	NFATC2
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	29.1×	0.037	SH2D1A
Innate Immune System	1	8.5×	0.113	ITK

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
B cell receptor signaling pathway	2	267.5×	5e-04	ITK, NFATC2
cellular defense response	2	212.0×	5e-04	SH2D1A, ITK
NK T cell differentiation	1	1404.3×	0.004	ITK
lncRNA transcription	1	1404.3×	0.004	NFATC2
myotube cell development	1	1123.5×	0.004	NFATC2
negative regulation of vascular associated smooth muscle cell differentiation	1	1123.5×	0.004	NFATC2
adaptive immune response	2	56.2×	0.004	SH2D1A, ITK
gamma-delta T cell activation	1	702.2×	0.006	ITK
positive regulation of myoblast fusion	1	351.1×	0.011	NFATC2
calcineurin-NFAT signaling cascade	1	280.9×	0.012	NFATC2
natural killer cell activation	1	193.7×	0.015	SH2D1A
positive regulation of natural killer cell mediated cytotoxicity	1	187.2×	0.015	SH2D1A
regulation of immune response	1	165.2×	0.016	SH2D1A
natural killer cell mediated cytotoxicity	1	144.0×	0.017	SH2D1A
negative regulation of T cell receptor signaling pathway	1	122.1×	0.018	SH2D1A
positive regulation of B cell proliferation	1	114.6×	0.018	NFATC2
humoral immune response	1	93.6×	0.020	SH2D1A
positive regulation of cytokine production	1	90.6×	0.020	ITK
T cell activation	1	86.4×	0.020	ITK
cartilage development	1	83.8×	0.020	NFATC2
cellular response to calcium ion	1	66.9×	0.024	NFATC2
T cell receptor signaling pathway	1	50.6×	0.030	ITK
transcription by RNA polymerase II	1	23.5×	0.058	NFATC2
cell-cell signaling	1	23.2×	0.058	SH2D1A
response to xenobiotic stimulus	1	23.0×	0.058	NFATC2
cell migration	1	20.5×	0.063	NFATC2
DNA damage response	1	17.8×	0.069	NFATC2
positive regulation of gene expression	1	12.9×	0.090	NFATC2
intracellular signal transduction	1	12.7×	0.090	ITK
regulation of DNA-templated transcription	1	10.5×	0.104	NFATC2

Therapeutics

Drugs indicated for this disease

2 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Idecabtagene Vicleucel	Approved (phase 4)
Tabelecleucel	Approved (phase 4)
MAS-825	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bortezomib, Leflunomide, Methylprednisolone, Prednisone, Rituximab.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ITK	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ITK	39	4
NFATC2	0	0
SH2D1A	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
FEDRATINIB	4	ITK
AXITINIB	4	ITK
IBRUTINIB	4	ITK
BOSUTINIB	4	ITK
ACALABRUTINIB	4	ITK
ZANUBRUTINIB	4	ITK
RITLECITINIB	4	ITK
NINTEDANIB	4	ITK
SUNITINIB	4	ITK
DASATINIB	4	ITK
QUIZARTINIB	4	ITK
CRIZOTINIB	4	ITK
CANERTINIB	3	ITK
EVOBRUTINIB	3	ITK
REMIBRUTINIB	3	ITK
DOVITINIB	3	ITK
LESTAURTINIB	3	ITK
FORETINIB	2	ITK
TANDUTINIB	2	ITK
SU-014813	2	ITK
REBASTINIB	2	ITK
CENISERTIB	2	ITK
ILORASERTIB	2	ITK
OSI-632	2	ITK
SPEBRUTINIB	2	ITK
BMS-986142	2	ITK
BMS-919373	2	ITK
ATUZABRUTINIB	2	ITK
CERDULATINIB	2	ITK
BRANEBRUTINIB	2	ITK

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ITK	563	Binding:547, Functional:10, ADMET:6
SH2D1A	5	Binding:5

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ITK	2.7.10.2	non-specific protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ITK	563

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

28 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
FEDRATINIB	4	ITK
AXITINIB	4	ITK
BOSUTINIB	4	ITK
ZANUBRUTINIB	4	ITK
RITLECITINIB	4	ITK
NINTEDANIB	4	ITK
SUNITINIB	4	ITK
DASATINIB	4	ITK
QUIZARTINIB	4	ITK
CRIZOTINIB	4	ITK
CANERTINIB	3	ITK
EVOBRUTINIB	3	ITK
REMIBRUTINIB	3	ITK
DOVITINIB	3	ITK
LESTAURTINIB	3	ITK
FORETINIB	2	ITK
TANDUTINIB	2	ITK
SU-014813	2	ITK
REBASTINIB	2	ITK
CENISERTIB	2	ITK
ILORASERTIB	2	ITK
OSI-632	2	ITK
SPEBRUTINIB	2	ITK
BMS-986142	2	ITK
BMS-919373	2	ITK
ATUZABRUTINIB	2	ITK
CERDULATINIB	2	ITK
BRANEBRUTINIB	2	ITK

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	ITK
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	NFATC2, SH2D1A

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
NFATC2	0	—
SH2D1A	5	—

Clinical trials & evidence

Clinical trials

Clinical trials: 105.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	31
PHASE1	26
PHASE2	25
PHASE3	11
PHASE1/PHASE2	7
PHASE2/PHASE3	4
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03394365	PHASE3	RECRUITING	A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT05770037	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770102	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770544	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT07440290	PHASE2/PHASE3	NOT_YET_RECRUITING	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT00033475	PHASE3	COMPLETED	Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
NCT00053053	PHASE3	COMPLETED	Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
NCT00058331	PHASE3	COMPLETED	Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
NCT00070382	PHASE3	COMPLETED	Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
NCT00516503	PHASE3	COMPLETED	Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00661999	PHASE3	COMPLETED	Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
NCT00666211	PHASE3	COMPLETED	Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
NCT00719563	PHASE3	COMPLETED	American Ginseng in Treating Patients With Fatigue Caused by Cancer
NCT00750009	PHASE3	COMPLETED	Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
NCT05431179	PHASE3	WITHDRAWN	A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00092222	PHASE2	ACTIVE_NOT_RECRUITING	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
NCT02579967	PHASE2	RECRUITING	Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
NCT02690545	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02861417	PHASE2	ACTIVE_NOT_RECRUITING	Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT03258567	PHASE2	RECRUITING	Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
NCT03663933	PHASE2	ACTIVE_NOT_RECRUITING	Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
NCT03922724	PHASE2	RECRUITING	Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
NCT04339777	PHASE2	RECRUITING	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
NCT04554914	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04858256	PHASE2	RECRUITING	Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT04883437	PHASE2	RECRUITING	Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
NCT00001379	PHASE2	COMPLETED	Treatment and Natural History Study of Lymphomatoid Granulomatosis
NCT00001438	PHASE2	COMPLETED	A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
NCT00048412	PHASE1/PHASE2	COMPLETED	Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
NCT00066469	PHASE2	COMPLETED	Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
NCT00255749	PHASE2	COMPLETED	Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00387530	PHASE2	WITHDRAWN	Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
NCT00416624	PHASE2	COMPLETED	Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
NCT00436618	PHASE2	COMPLETED	Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
NCT00579111	PHASE1/PHASE2	TERMINATED	Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
NCT00621036	PHASE2	WITHDRAWN	Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
NCT00823524	PHASE1/PHASE2	COMPLETED	Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
NCT00869323	PHASE2	TERMINATED	Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
NCT00992732	PHASE2	TERMINATED	Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
NCT01101412	PHASE1/PHASE2	WITHDRAWN	Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EPOETIN ALFA	4	4
AMITRIPTYLINE	4	3
TABELECLEUCEL	4	3
VALGANCICLOVIR	4	3
DARBEPOETIN ALFA	4	2
PACRITINIB	4	2
PHENYLBUTANOIC ACID	4	2
ACALABRUTINIB	4	1
ALCOHOL	4	1
ALECTINIB	4	1
BACLOFEN	4	1
DABRAFENIB	4	1
DAPSONE	4	1
EDETATE CALCIUM DISODIUM MONOHYDRATE	4	1
ENTRECTINIB	4	1
EPOETIN BETA	4	1
FENTANYL CITRATE	4	1
FERROUS SULFATE	4	1
FLUDEOXYGLUCOSE F 18	4	1
GANCICLOVIR	4	1
IBRUTINIB	4	1
IMETELSTAT SODIUM	4	1
LEFLUNOMIDE	4	1
METHADONE HYDROCHLORIDE	4	1
MORPHINE SULFATE	4	1
ONDANSETRON HYDROCHLORIDE	4	1
OXYCODONE HYDROCHLORIDE	4	1
PENTOSTATIN	4	1
PLERIXAFOR	4	1
PYRIMETHAMINE	4	1